Clinical outcome of Crohn's disease treated with infliximab

Arslan S., Kav T., Besisik F., Kaymakoglu S., Pinarbasi B., Tozun N., ...More

HEPATO-GASTROENTEROLOGY, vol.50, no.52, pp.952-956, 2003 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 52
  • Publication Date: 2003
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.952-956
  • Hacettepe University Affiliated: No


Background/Aims: Controlled studies in humans have shown the role of antibodies to tumor necrosis factor-alpha in the treatment of both fistulizing and inflammatory Crohn's disease. The aim of this study is to report the results of a multicenter clinical trial to evaluate efficacy of infliximab in Crohn's disease patients who are refractory to conservative drugs or fistulizing Crohn's disease.